Gilead Sciences (GILD) Total Liabilities (2009 - 2026)

Gilead Sciences (GILD) has reported Total Liabilities for 18 consecutive years, with $37.5 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 3.88% year-over-year to $37.5 billion; the trailing twelve-month figure through Jun 2026 stood at $37.5 billion (up 3.88% YoY), and the FY2025 full-year result was $36.3 billion, down 8.63% from the prior year.
• Total Liabilities climbed to $37.5 billion in Q2 2026 per GILD's latest filing, from $32.8 billion in the prior quarter.
• Across five years, Total Liabilities topped out at $43.2 billion in Q1 2022 and bottomed at $32.8 billion in Q1 2026.
• Historically, Total Liabilities has averaged $38.8 billion across 5 years, with a median of $39.1 billion in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Liabilities slipped 14.21% in 2024, then advanced 3.88% in 2026.
• Over 5 years, Total Liabilities stood at $42.0 billion in 2022, then dropped by 6.16% to $39.4 billion in 2023, then grew by 0.95% to $39.7 billion in 2024, then slipped by 8.63% to $36.3 billion in 2025, then gained by 3.34% to $37.5 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $37.5 billion, $32.8 billion, and $36.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.